Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia

Abstract

Treatment with long-acting injectable risperidone compared with previous antipsychotic medications resulted in a higher number of patients not requiring hospitalization, not relapsing, and not requiring hospitalization and not showing relapse, resulting in risperidone being more cost effective per month per patient.It is important to note that real-world variations in adherence would automatically be controlled from within a randomized control trial, and hence, any evaluation of variations in adherence inevitably requires a real-world focus. On the basis of these findings, which were obtained in real-world clinical practice, long-acting injectable risperidone is predicted to be the dominant strategy because it results in effective symptom control and direct medical cost savings. However, because of limitations in methodology, any conclusions should, at this stage, be treated as tentative, and confirmation in more detailed follow-up studies is required. Cost-effectiveness comparisons based on experimental evaluations of relapse minimization strategies are also required. In order to avoid estimation biases in the future, a prospectively designed study is needed.

Cost Effectiveness of Long-Acting Risperidone in Sweden

“…[59][60][61] These studies suggest that RLAI is associated with reductions in hospitalization, [59][60][61] and that the financial savings from reduced hospital days exceed the acquisition costs of RLAI, [59,60] which is similar to the results presented here.…”

Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery

“…LAI antipsychotics have been shown to reduce the risk of relapse, symptom-related outcomes, healthcare resource utilization (i.e., hospitalization rates), and inpatient and outpatient healthcare costs [21][22][23][24][25] . In addition to these benefits, a recent study indicated that LAI antipsychotics may 26 .…”

Registro Electrónico de Adherencia al Tratamiento de Esquizofrenia en Latinoamérica (e-STAR): Resultados clínicos del uso de risperidona inyectable de liberación prolongada a dos años de seguimiento

“…La RILP es un tratamiento que, además de ser eficaz en el manejo de los síntomas de la enfermedad, permite una adecuada adherencia al tratamiento por parte de los pacientes, lo que disminuye el número de hospitalizaciones y tiempo de estancia intrahospitalaria. 5,19,23,27,31,37,[51][52][53] Una de las principales implicaciones de estos resultados se encuentra dirigida a las concepciones en torno al uso de antipsicóticos inyectables como tratamiento de primera elección para la esquizofrenia, incluso en situaciones clínicas no relacionadas con dificultades en la adherencia al tratamiento. Con el uso de la RILP, los pacientes se verían beneficiados por un antipsicótico eficaz para el tratamiento de los síntomas, el cual no tiene que ser tomado diariamente, lo que aumenta las probabilidades de una adecuada adherencia y reduce las posibilidades de una recaída y eventual hospitalización.…”